

# Nathan Constantine-Cooke

## Curriculum Vitae

REDACTED

✉ [nathan.constantine-cooke@ed.ac.uk](mailto:nathan.constantine-cooke@ed.ac.uk)

🌐 [constantine-cooke.com](https://constantine-cooke.com)

📖 [Google Scholar](#) [in LinkedIn](#) [Github](#)

## Education

- 2019–2023 **PhD, Precision Medicine**, *University of Edinburgh*, Edinburgh, Scotland.  
*Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease*
- 2018–2019 **Master of Science, Statistics for Computational Biology (Distinction)**, *Aberystwyth University*, Aberystwyth, Wales.
- 2014–2018 **Bachelor of Science (Hons), Mathematics (2:1)**, *Aberystwyth University*, Aberystwyth, Wales.

## Publications

### Articles Under Review

- 2024 **Nathan Constantine-Cooke**, Marie Vibeke Vestergaard, Nikolas Plevris, Karla Monterrubio-Gómez, Clara Ramos Belinchón, Solomon Ong, Alexander T. Elford, Beatriz Gros, Aleksejs Sazonovs, Gareth-Rhys Jones, Tine Jess, Catalina A. Vallejos, and Charlie W. Lees. Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease, November 2024.

### Journal Articles

- 2025 **Nathan Constantine-Cooke**, Alexander T. Elford, Phil W. Jenkinson, Beatriz Gros, Nikolas Plevris, Mathew Lyons, Solomon Ong, Neil Greenlees, Victor Velasco-Pardo, Claire O'Hare, Nicholas T. Ventham, Paul Henderson, David C. Wilson, Shahida Din, Colin L. Noble, Gareth-Rhys Jones, Ian Arnott, and Charlie W. Lees. Twenty-Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland. *Alimentary Pharmacology & Therapeutics*, page apt.70240, June 2025.
- 2025 Beatriz Gros, Mairi Goodall, Nik Plevris, **Nathan Constantine-Cooke**, Alexander T Elford, Claire O'Hare, Colin Noble, Gareth-Rhys Jones, Ian D Arnott, and Charlie W Lees. Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis. *Journal of Crohn's and Colitis*, volume 19, page jjad187, January 2025.
- 2024 **Nathan Constantine-Cooke**, Beatriz Gros, Jake Kennedy, Alexander T Elford, Claire O'Hare, Colin Noble, Gareth-Rhys Jones, Ian D Arnott, Charlie W Lees, and Nikolas Plevris. Tofacitinib versus vedolizumab among bio-naïve patients with ulcerative colitis: A real-world propensity-weighted comparison. *Journal of Crohn's and Colitis*. Oxford University Press (OUP), December 2024.
- 2024 **Nathan Constantine-Cooke**, Beatriz Gros, , Jake Kennedy, Alexander T Elford, Claire O'Hare, Colin Noble, Gareth-Rhys Jones, Ian D Arnott, Charlie W Lees, and Nikolas Plevris. Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison. *Journal of Crohn's and Colitis*, page jjae188, December 2024.
- 2024 Karla Monterrubio-Gómez, **Nathan Constantine-Cooke**, and Catalina A. Vallejos. A review on statistical and machine learning competing risks methods. *Biometrical Journal*, volume 66. Wiley, February 2024.

- 2024 Beatriz Gros, Hannah Ross, Maureen Nwabueze, **Nathan Constantine-Cooke**, Lauranne A. A. P. Derikx, Mathew Lyons, Claire O'Hare, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees, and Nikolas Plevris. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis. *Therapeutic Advances in Gastroenterology*, volume 17. SAGE Publications, January 2024.
- 2024 Alexander Thomas Elford, Maria Bishara, Nikolas Plevris, Beatriz Gros, **Nathan Constantine-Cooke**, Nicholas A Kennedy James Goodhand, Tariq Ahmad, and Charlie W. Lees. Real-world effectiveness of upadacitinib in Crohn's disease: A UK multicentre retrospective cohort study. *Frontline Gastroenterology*, volume 15, page 297–304. BMJ, April 2024.
- 2023 **Nathan Constantine-Cooke**, Karla Monterrubio-Gómez, Nikolas Plevris, Lauranne A.A.P Derikx, Beatriz Gros, Gareth-Rhys Jones, Riccardo E.Marioni, Charlie W. Lees, and Catalina A. Vallejos. Longitudinal fecal calprotectin profiles characterize disease course heterogeneity in Crohn's disease. *Clinical Gastroenterology and Hepatology*, volume 21, pages 2918–2927.e6. Elsevier, October 2023.
- 2023 Beatriz Gros, Nikolas Plevris, **Nathan Constantine-Cooke**, Mathew Lyons, Claire O'Hare, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees, and Lauranne A. A. P. Derikx. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort. *United European Gastroenterology Journal*. Wiley, February 2023.
- 2023 Beatriz Gros, Mairi Goodall, Nik Plevris, **Nathan Constantine-Cooke**, Alexander T Elford, Claire O'Hare, Colin Noble, Gareth-Rhys Jones, Ian D Arnott, and Charlie W Lees. Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis. *Journal of Crohn's and Colitis*. Oxford University Press, December 2023.
- 2022 Mathew Lyons, Lauranne A. A. P. Derikx, James Fulforth, Sophie McCall, Nikolas Plevris, Philip W. Jenkinson, Kathryn Kirkwood, Spyros Siakavellas, Laura Lucaciu, **Nathan Constantine-Cooke**, Ian D. Arnott, Paul Henderson, Richard K. Russell, David C. Wilson, Charlie W. Lees, and Gareth-Rhys Jones. Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: A retrospective prevalent cohort analysis. *Alimentary Pharmacology & Therapeutics*. Wiley, March 2022.
- 2022 Lauranne A.A.P. Derikx, Nikolas Plevris, Shanna Su, Beatriz Gros, Mathew Lyons, Spyros I. Siakavellas, **Nathan Constantine-Cooke**, Philip Jenkinson, Claire O'Hare, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, and Charlie W Lees. Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease. *Digestive and Liver Disease*, October 2022.
- 2021 **Nathan Constantine-Cooke**, Laura A. Lucaciu, Nikolas Plevris, Spyros Siakavellas, Laurantanne A.A.P. Derikx, Gareth-Rhys Jones, and Charles W. Lees. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. *Therapeutic Advances in Gastroenterology*, volume 14, page 17562848211064004, December 2021. PMID: 34987608.
- 2021 Laurantanne A A P "Derikx, Heather W Dolby, Nikolas Plevris, Laura Lucaciu, Caitlin S Rees, Mathew Lyons, Spyros I Siakavellas, **Nathan Constantine-Cooke**, Philip Jenkinson, Shanna Su, Claire O'Hare, Laura Kirckpatrick, Lynne M Merchant, Colin Noble, Ian D Arnott, Gareth-Rhys Jones, and Charlie W Lees. Effectiveness and safety of adalimumab biosimilar SB5 in IBD: Outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve SB5 observational cohorts. *Journal of Crohn's and Colitis*. Elsevier, June 2021.

#### Conference Proceedings

- 2023 **Nathan Constantine-Cooke**, Karla Monterrubio-Gómez, Nikolas Plevris, Laurantanne A.A.P. Derikx, Matthew Lyons, Phillip W. Jenkinson, Beatriz Gros, Gareth-Rhys Jones, Catalina A Vallejos, and Charlie W. Lees. P789 Inflammatory Bowel Disease subgroups identified by longitudinal faecal calprotectin profiles: A 10-year retrospective analysis of the Lothian IBD Registry. *Journal of Crohn's and Colitis*, volume 17, pages i921–i924, 01 2023.

- 2022 **Nathan Constantine-Cooke**, Karla Monterrubio-Gomez, Nikolas Plevris, Laurantne A.A.P Derikx, Beatriz Gros, Gareth-Rhys Jones, Riccardo Marioni, Charlie Lees, and Catalina Vallejos. P0351 Latent Crohn's disease subgroups are identified by faecal calprotectin profiles: A retrospective analysis of the Lothian Crohn's disease inception cohort. *United European Gastroenterology Journal*, pages S687–S688, 05 2022.

---

## Research Experience

University of Edinburgh, Edinburgh, UK

2019 – **Longitudinal Modelling of Disease Activity Biomarkers in Inflammatory Bowel Disease.**

Present Using latent class mixed models to identify latent homogenous subgroups in the highly heterogenous inflammatory bowel disease patient population from faecal calprotectin and CRP profiles.

Advisor : **Dr Catalina Vallejos**, Reader, MRC Human Genetics Unit ([Personal Web-page](#))

Advisor : **Professor Charlie Lees**, Professor of Gastroenterology, Centre for Genomic and Experimental Medicine ([Personal Web-page](#))

2020 – 2021 **Meta-Analysis of the Real-World Effectiveness and Safety of Tofacitinib.**

Advisor : **Professor Charlie Lees**, Professor of Gastroenterology, Centre for Genomic and Experimental Medicine

2020 – 2021 **Using Data Science to Answer Pressing Emergency Care Questions Surrounding COVID-19 (DECOVID).**

Advisor : **Dr Catalina Vallejos**, Reader, MRC Human Genetics Unit

Aberystwyth University, Aberystwyth, UK

2018 – 2019 **Analysis Techniques Applicable to Time-Limited Gene Expression Data.**

Investigated approaches applicable to detecting rhythmic gene expression patterns when followup is limited and proposed a novel approach. Circadian, circatidal, and circalunar gene expression in *Talitrus saltator* was explored.

Advisor : **Dr Kim Kenobi**, Lecturer, Department of Mathematics ([Personal Web-page](#))

---

## Academic Reviews

2023 **Gastroenterology.**

One manuscript

2023 **Inflammatory bowel diseases.**

One manuscript

---

## Computer Languages

Scripting R, Python, Bash

Programming C++, Rust

Markup L<sup>A</sup>T<sub>E</sub>X, HTML 5 & CSS, and Markdown

Other Tools GNU Make, Git (including CI workflows), Docker & Singularity, Unix, and Jekyll

---

## Teaching

Ed-DaSH Workshops

Sep 2022 **Introduction to Statistics with R.**

Jun 2022 **Introduction to Statistics with R.**

May 2022 **High-Dimensional Statistics with R.**

Jan 2022 **Introduction to Statistics with R.**

Aberystwyth University

2018-2019 **Undergraduate Demonstrator (Mathematics).**

---

## Referees

### **Prof Charlie Lees**

*Chair of Gastroenterology*

*Centre for Genomic and Experimental Medicine*

University of Edinburgh

✉ [charlie.lees@ed.ac.uk](mailto:charlie.lees@ed.ac.uk)

### **Dr Catalina Vallejos**

*Reader*

*MRC Human Genetics Unit*

University of Edinburgh

✉ [cvallejo@ed.ac.uk](mailto:cvallejo@ed.ac.uk)